Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BIMZELX vs BIMATOPROST
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
BIMZELX (bimekizumab) is a humanized monoclonal Ig G1 antibody that selectively neutralizes interleukin-17A (IL-17A) and interleukin-17F (IL-17F), inhibiting their binding to the IL-17 receptor and subsequent pro-inflammatory signaling.
Bimatoprost is a synthetic prostamide analog that selectively mimics the effects of prostamide F2α. It binds to prostaglandin F (FP) receptors on ciliary muscle cells and trabecular meshwork cells, increasing uveoscleral outflow and possibly trabecular outflow of aqueous humor, thereby reducing intraocular pressure. It also directly stimulates the prostaglandin FP receptor, leading to increased matrix metalloproteinase activity and remodeling of the extracellular matrix in the ciliary body.
Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy,Active psoriatic arthritis in adults,Active ankylosing spondylitis in adults
Reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension,Hypotrichosis of the eyelashes (off-label use for eyelash growth promotion)
Subcutaneous injection: 160 mg (two 80 mg injections) at week 0, week 2, week 4, then every 4 weeks.
One drop of 0.01% or 0.03% ophthalmic solution instilled into the affected eye(s) once daily in the evening.
Terminal elimination half-life is approximately 26 days (range 22–29 days) across approved doses; supports every 4-week subcutaneous dosing.
Terminal half-life: ~45 minutes (intravenous); after topical ocular administration, systemic half-life is similar due to rapid systemic clearance, with clinical effect lasting 24 hours due to ocular tissue binding
Bimekizumab is likely degraded into small peptides and amino acids via general protein catabolism. It is not metabolized by CYP450 enzymes.
Bimatoprost is rapidly metabolized via hydrolysis to the more active free acid form by esterases in the cornea and plasma. Further metabolism occurs via oxidation, reduction, and conjugation, primarily in the liver. The major enzymes involved are hepatic cytochrome P450 (CYP) isozymes, with CYP2C9 and CYP3A4 contributing to minor oxidative metabolites. The free acid is subsequently glucuronidated.
Bimekizumab is a monoclonal antibody that is degraded into small peptides and amino acids via general protein catabolism; no renal or biliary excretion of intact antibody. Fecal excretion of degraded fragments is minor (<1%).
Renal: <67% (unchanged and metabolites), Biliary/fecal: ~25%
Approximately 99% bound to target (IL-17A and IL-17F) in serum; albumin binding is negligible.
~88% bound to albumin
Volume of distribution at steady state is approximately 7.0 L (0.1 L/kg assuming 70 kg), indicating limited extravascular distribution, consistent with a monoclonal antibody primarily in plasma and interstitial fluid.
0.3–0.4 L/kg (indicates distribution primarily into extracellular fluid)
Subcutaneous: Approximately 80% (range 60–100%) compared to intravenous administration.
Topical ocular: low systemic absorption (~50% absorbed into ocular tissues, with negligible systemic bioavailability due to hydrolysis in plasma)
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (e GFR <30 m L/min/1.73 m2).
No dose adjustment required for renal impairment; no specific GFR-based guidelines.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C).
Use with caution in severe hepatic impairment (Child-Pugh class C); no specific dose adjustments established.
Safety and efficacy not established in pediatric patients.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
No specific dose adjustment recommended; pharmacokinetics similar to younger adults in clinical studies with patients up to 75 years.
No specific dose adjustment required; same dosing as adults, but monitor for increased systemic absorption due to age-related ocular surface changes.
None.
None
Increased risk of infections, including serious infections; avoid use during active infection,Hypersensitivity reactions including urticaria and angioedema,Exacerbation of inflammatory bowel disease (Crohn's disease or ulcerative colitis),Potential for increased suicidality or depression; monitor for neuropsychiatric symptoms,Avoid live vaccines during treatment,Tuberculosis screening prior to initiation
May cause gradual, permanent changes to eyelashes (increased length, thickness, pigmentation) and periorbital tissue (darkening and deepening of the upper eyelid sulcus). Increased iris pigmentation (iridal melanocytes) is irreversible. Use with caution in patients with hepatic or renal impairment. Risk of macular edema, particularly in aphakic or pseudophakic patients with a torn posterior lens capsule. May exacerbate uveitis or cystoid macular edema. Contains benzalkonium chloride; avoid in patients with hypersensitivity to this preservative. Discontinue if signs of systemic absorption occur (e.g., flushing, hypotension).
Known hypersensitivity to bimekizumab or any excipient,Active tuberculosis or other severe infections
Hypersensitivity to bimatoprost or any component of the formulation. Active intraocular inflammation (e.g., uveitis). Macular edema. Caution in patients with hepatic or renal impairment. Relative contraindication in pregnancy (category C) and breastfeeding.
There are no known food interactions with BIMZELX. Take with or without food.
No significant food interactions. No dietary restrictions are required.
Bimekizumab is a humanized monoclonal Ig G1 antibody that inhibits IL-17A and IL-17F. As a large protein, it is transported across the placenta via Fc Rn-mediated transfer, with fetal levels increasing during the second and third trimesters. Available data are insufficient to determine a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal studies showed no evidence of teratogenicity or fetal harm in monkeys at doses up to 100 mg/kg (approximately 30 times the human exposure at the recommended dose). However, monoclonal antibodies are known to cross the placenta, and the theoretical risk of fetal immune suppression exists. Therefore, bimekizumab should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Bimatoprost is a prostaglandin analog. Animal studies have shown embryofetal toxicity including skeletal malformations and increased post-implantation loss at doses >30 times the human exposure. There are no adequate and well-controlled studies in pregnant women. Risk cannot be ruled out; avoid use in pregnancy unless benefit outweighs risk. First trimester: potential teratogenicity. Second and third trimesters: potential for premature labor or uterine hyperstimulation due to oxytocic effects.
It is unknown whether bimekizumab is excreted in human milk or absorbed systemically after ingestion. Monoclonal antibodies are generally present in breast milk at very low concentrations with limited oral bioavailability due to protein digestion in the infant's gastrointestinal tract. The M/P ratio has not been determined. Due to the potential for adverse reactions in the breastfed infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Bimatoprost is excreted in rat milk, but no human data exist. The molecular weight (415.57 Da) suggests possible excretion into human breast milk. The M/P ratio is unknown. Because of the potential for serious adverse reactions in nursing infants, especially from systemic effects of prostaglandin analogs, breastfeeding is not recommended during treatment or for 6 hours after ophthalmic administration.
No dose adjustment is recommended during pregnancy based on pharmacokinetic changes. Bimekizumab clearance is not expected to be significantly altered by pregnancy-related physiological changes. However, given the limited data, the drug should be used only if clearly needed. Monitor clinical response and adjust dose if necessary (though no standard guidelines exist).
Pregnancy induces physiological changes (increased plasma volume, renal clearance, and hepatic metabolism) that may reduce systemic drug concentrations. For bimatoprost ophthalmic solution, negligible systemic absorption occurs, so no dose adjustment is required. In case of systemic use, close monitoring and potential dose adjustments based on clinical response are warranted, but specific guidelines are unavailable.
BIMZELX (bimekizumab) is a humanized monoclonal Ig G1 antibody that selectively inhibits both IL-17A and IL-17F. It is administered subcutaneously with a loading dose at weeks 0, 2, 4, then every 8 weeks. Monitor for exacerbations of inflammatory bowel disease (Crohn's or ulcerative colitis) as IL-17 inhibition can rarely trigger or worsen these conditions. Do not administer live vaccines during treatment. Consider tuberculosis screening prior to initiation.
Bimatoprost is a prostaglandin analog used for lowering intraocular pressure (IOP) in open-angle glaucoma or ocular hypertension. It increases uveoscleral outflow. Administer once daily in the evening. Do not exceed once-daily dosing as it may reduce efficacy. Touching the dropper tip to the eye or surrounding structures can contaminate the solution. Remove contact lenses before instillation and wait 15 minutes before reinserting. Common side effects include conjunctival hyperemia, eyelash growth, and periorbital pigmentation. Monitor for cystoid macular edema in aphakic or pseudophakic patients with a torn posterior lens capsule. Use with caution in patients with active intraocular inflammation (e.g., iritis/uveitis).
You may be at increased risk of infections, including upper respiratory tract infections and oral candidiasis. Report any signs of infection to your healthcare provider promptly.,If you have a history of inflammatory bowel disease (Crohn's disease or ulcerative colitis), tell your doctor before starting treatment, as this medicine can worsen it.,Do not receive live vaccines while on BIMZELX. Discuss any required vaccinations with your doctor before starting therapy.,This medication is given as an injection under the skin. You or your caregiver can be trained to administer it at home. Rotate injection sites and do not inject into tender, bruised, or scarred skin.,Store BIMZELX in the refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light. Keep in original carton until use.
Use exactly as prescribed; do not use more than once a day.,Apply in the evening to maximize effectiveness.,Wash hands before and after application.,Remove contact lenses before using and wait 15 minutes before reinserting.,Do not let the dropper tip touch your eye or any surface.,If using more than one eye drop, wait at least 5 minutes between applications.,May cause temporary blurred vision; do not drive until vision clears.,May gradually darken eyelid skin and increase eyelash growth; this is reversible upon discontinuation.,Report any eye pain, vision changes, or signs of infection (redness, swelling) to your doctor.,Store at room temperature away from light and moisture.
No interactions on record
"Azelastine, an antihistamine, may reduce the intraocular pressure-lowering efficacy of bimatoprost, a prostaglandin analog used for glaucoma. This interaction is postulated to occur via antagonism of the prostaglandin F2α receptor or through pharmacodynamic opposition, as antihistamines can interfere with the outflow enhancement mechanism of bimatoprost. Clinically, this may result in inadequate intraocular pressure control, necessitating dose adjustment or alternative therapy."
"Pirfenidone, an antifibrotic agent, may reduce the ocular hypotensive efficacy of bimatoprost, a prostaglandin analog used for glaucoma. This interaction is postulated to occur via pirfenidone's inhibitory effects on prostaglandin synthesis or signaling pathways, potentially attenuating bimatoprost-mediated enhancement of uveoscleral outflow. Clinically, patients may experience inadequate intraocular pressure (IOP) reduction, increasing the risk of glaucoma progression."
"Eprosartan, an angiotensin II receptor blocker (ARB), reduces blood pressure by inhibiting the vasoconstrictor and aldosterone-secreting effects of angiotensin II. Bimatoprost, a prostaglandin analog used for glaucoma, lowers intraocular pressure but can also cause systemic vasodilation, potentially leading to additive hypotensive effects. This interaction may result in excessive lowering of blood pressure, particularly in patients with compromised cardiovascular function or those on multiple antihypertensive agents."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BIMZELX vs BIMATOPROST, answered by our medical review team.
BIMZELX is a Prostaglandin Analog that works by BIMZELX (bimekizumab) is a humanized monoclonal Ig G1 antibody that selectively neutralizes interleukin-17A (IL-17A) and interleukin-17F (IL-17F), inhibiting their binding to the IL-17 receptor and subsequent pro-inflammatory signaling.. BIMATOPROST is a Prostaglandin Analog that works by Bimatoprost is a synthetic prostamide analog that selectively mimics the effects of prostamide F2α. It binds to prostaglandin F (FP) receptors on ciliary muscle cells and trabecular meshwork cells, increasing uveoscleral outflow and possibly trabecular outflow of aqueous humor, thereby reducing intraocular pressure. It also directly stimulates the prostaglandin FP receptor, leading to increased matrix metalloproteinase activity and remodeling of the extracellular matrix in the ciliary body.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BIMZELX and BIMATOPROST depend on the specific clinical indication. These are both Prostaglandin Analog agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BIMZELX is: Subcutaneous injection: 160 mg (two 80 mg injections) at week 0, week 2, week 4, then every 4 weeks.. The standard adult dose of BIMATOPROST is: One drop of 0.01% or 0.03% ophthalmic solution instilled into the affected eye(s) once daily in the evening.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BIMZELX and BIMATOPROST in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BIMZELX is classified as Category C. Bimekizumab is a humanized monoclonal IgG1 antibody that inhibits IL-17A and IL-17F. As a large protein, it is transported across the placenta via FcRn-mediated transfer, with feta. BIMATOPROST is classified as Category C. Bimatoprost is a prostaglandin analog. Animal studies have shown embryofetal toxicity including skeletal malformations and increased post-implantation loss at doses >30 times the h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.